

BEYOND THE GUIDELINES: CLINICAL PERSPECTIVES ON THE MANAGEMENT OF GENITOURINARY TUMORS

SAVE THE DATE

8th - 9th July, 2022

6:30 - 9:10 pm

Program Directors



Dr. Hemant Malhotra

Director, Oncology Services, Sri Ram Cancer & Super Speciality Center & Prof. & Head, Dept. of Medical Oncology, Mahatma Gandhi Medical College Hospital, Jaipur



Dr. Sadashivudu Gundeti

Additional Professor & HOD, Nizam's Institute of Medical Sciences, Hyderabad

Click here for disclaimer



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India



BEYOND THE GUIDELINES: CLINICAL PERSPECTIVES ON THE MANAGEMENT OF GENITOURINARY TUMORS

8th - 9th July, 2022

8th July 2022 | 6:30-9:10 pm

Day 1

Scientific Program ————	
6:30 - 6:40 pm	Welcome and Introduction Program Director & Pfizer Medical
6:40 - 7:00 pm	Current Treatment landscape for first line therapy for urothelial carcinoma Speaker: Dr. Meenu Walia
7:00 - 7:30 pm	Challenges in selecting first-line therapy for urothelial carcinoma – • Current first-line therapy guidelines and recommendations • Clinical scenarios in which ICI therapy is the optimal treatment course • Cisplatin-ineligible patients • PD-L1 expression and agent specific assays and expression thresholds Speaker: Dr. Thomas Powles
7:30 - 7:50 pm	Treatment Refractory advanced urothelial cancer

Sequencing strategies, considerations, and

challenges Speaker: Dr. B J Srinivas

7:50 - 8:10 pm

Key studies in urothelial carcinoma-Conference highlights from ASCO GU 2022 and


ASCO

Speaker: Dr. Chirag Desai

Click here for disclaimer



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India



BEYOND THE GUIDELINES: CLINICAL PERSPECTIVES ON THE MANAGEMENT OF GENITOURINARY TUMORS

8th - 9th July, 2022

8th July 2022 | 6:30-9:10 pm

Day 1

Scientific Program

8:10 - 8:25 pm Case presentation - An Indian Perspective

Critical analysis of the case Speaker: Dr. P S Dattatreya

8:25 - 8:40 pm Panel Discussion: Considerations related to

everyday clinical practice Moderator : Dr. Vineet Talwar

Panelists: All speakers

Chairperson : Dr. Rajat Saha

8:40 - 9:00 pm Debate:

What is the best strategy for management of

cisplatin ineligible patients: Gem-carbo

followed by IO maintenance or IO

monotherapy

For : Dr. Biwas Biswas Against : Dr. Priya Tiwari

9:00 - 9:05 pm Live Q and A

9:05 - 9:10 pm Closing Remarks

Program Director & Pfizer Medical

Click here for disclaimer



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

Ear the use only of Dedictored Medical Dractitioners or a Hospital or a Laborat



BEYOND THE GUIDELINES: CLINICAL PERSPECTIVES ON THE MANAGEMENT OF GENITOURINARY TUMORS

8th - 9th July, 2022

9th July 2022 | 6:30-9:10 pm

Day 2

Scientific Program

	3 3 3 3 1 3 3 1 3 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1
6:30 - 6:40 pm	Welcome and Introduction Program Director & Pfizer Medical
6:40 - 7:00 pm	Current Treatment landscape for first line therapy for renal cell carcinoma Speaker: Dr. Mohit Agarwal
7:00 - 7:30 pm	Immuno-Oncology combinations in Advanced RCC: Building on recent progress and improving patient outcomes Speaker: Dr. Enrique Grande
7:30 - 7:50 pm	Treatment Refractory advanced renal cell carcinoma-Second line therapy and beyond • Sequencing strategies, considerations, and challenges Speaker: Dr. Amit Joshi
7:50 - 8:10 pm	Key studies in metastatic renal carcinoma- Conference highlights from ASCO GU 2022 and ASCO Speaker: Dr. Vindhya Vasini
8:10 - 8:25 pm	Case presentation- An Indian Perspective Critical analysis of the case Speaker: Dr. P N Mohapatra
8:25 - 8:40 pm	Panel Discussion : Considerations related to everyday clinical practice and discussion Moderator : Dr. Prasad Narayanan Panelists : All speakers

Click here for disclaimer



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India



BEYOND THE GUIDELINES: CLINICAL PERSPECTIVES ON THE MANAGEMENT OF GENITOURINARY TUMORS

8th - 9th July, 2022

9th July 2022 | 6:30-9:10 pm

Day 2

Scientific Program

ondir per

Chairperson : Dr. Kumar Prabhash

8:40 - 9:00 pm

Debate:

Immune Checkpoint Inhibitor Combination

Therapy versus TKI alone as First-Line Treatment for Favorable-IMDC-Risk Advanced

Renal Cell Carcinoma Patients

For: Dr. Ashish Singh

Against: Dr. Ravi Thippeswamy

9:00 - 9:05 pm

Live Q and A

9:05 - 9:10 pm

Closing Remarks

Program Director & Pfizer Medical

Webinar Management

rive (Coute

Mobile: +91 9082484474 E-mail: rrcg.pravin@gmail.com

Click here for disclaimer



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India